Instrument Inactif

Communiqués Flexion Therapeutics, Inc.

Actions

FLXN

US33938J1060

Recherche biotechnologique et médicale

Communiqués

19/11/21	FLEXION THERAPEUTICS INC : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, (form 8-K)	AQ
12/11/21	FLEXION THERAPEUTICS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
12/10/21	FLEXION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN	BU
12/10/21	FLEXION THERAPEUTICS INC : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
01/10/21	Flexion Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
08/09/21	Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference	GL
06/09/21	Flexion Therapeutics : to Present at the Wells Fargo 2021 Virtual Healthcare Conference	AQ
03/09/21	Flexion Therapeutics : Announces Inclusion of ZILRETTA in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee	AQ
03/09/21	Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference	GL
02/09/21	Flexion Therapeutics : Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee	AQ
25/08/21	Flexion Therapeutics : Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain	AQ
09/08/21	Flexion Therapeutics : Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)	AQ
05/08/21	Flexion Therapeutics : Q2 2021 Commercial Metrics Overview - August 4, 2021	PU
04/08/21	Flexion Therapeutics : Reports Second-Quarter 2021 Financial Results and Recent Business Highlights (Form 8-K)	PU
04/08/21	Flexion Therapeutics: Q2 Earnings Snapshot	AQ
04/08/21	FLEXION THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
04/08/21	Flexion Therapeutics : Reports Second-Quarter 2021 Financial Results and Recent Business Highlights	AQ
29/07/21	Flexion Therapeutics : to Report Second-Quarter 2021 Financial Results on August 4, 2021	AQ
12/07/21	FLEXION THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-K)	AQ
12/07/21	Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors	GL
05/07/21	Flexion Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
02/07/21	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
25/06/21	FLEXION THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
18/06/21	Flexion Therapeutics: Q1 Earnings Snapshot	AQ
14/06/21	Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference	GL